Skip to main content

WORK PACKAGE 2

WP2: Phenotyping for personalized medicine

The aim of WORK PACKAGE 2 is to identify biomarkers and genetic/epigenetic markers for treatment effect and severity of disease, as well as to characterize and stratify early disease.

The work package will have professional responsibility for biobanking in the clinical trial unit (CTU).

More about the projects included in or associated with WORK PACKAGE 2:

WP1 - Optimized medical interventions

ARCTIC

Remission in patients with rheumatoid arthritis: a randomized controlled trial investigating the use of ultrasound in clinical follow-up

Project Manager:
Espen A. Haavardsholm
WP1 - Optimized medical interventions

ARCTIC REWIND

 

Project managers

Post doc
PhD fellow

ABOUT THE PROJECT

Rheumatoid arthritis is an inflammatory disease affecting 0.5-1% of the population. The disease is characterized by joint lifts and joint pain, which can lead to joint damage and reduced functional level. Using modern treatment strategies, which include disease -modifying drugs, good disease control without signs of inflammation has become an achievable measure of an ever -increasing number of people. However, there has been no professional agreement or clear guidelines for how this group should be treated further; Should one continue with a stable dose of medication, or step down and possibly end treatment?

Arctic Rewind is a randomized controlled multi -center study where the main goal is to investigate whether a strategy in which the disease -modifying treatment is reduced and possibly discontinued is not inferior to still stable treatment when it comes to taking care of good disease control. In addition, the study will provide sought -after data for research on more personalized treatment.

WHO CAN JOIN?

The study included adults with rheumatoid arthritis where there had been no signs of activity in the disease last 12 months. Both recruitment and follow -up of the included have been completed.

WHAT DOES THE STUDY INVOLVE?

In one study arm, the treatment was stepped down and possibly discontinued, in the other, participants continued unchanged treatment. Both groups were followed with regular checks every 4 months for 3 years with thorough mapping of signs of flare -up of activity in the disease (clinical examination, blood tests and patient -reported outcome measures), as well as registration and handling of potential side effects. In addition, ultrasound examination, x -ray of hands and feet, was carried out by dominant hand and biobank.

The study was divided into two; One part included people who used synthetic disease-modifying treatment, the other included people who used biological drugs (TNF inhibitors).

MENTION

Arctic Rewind: New Norwegian study can change how we treat arthritis (Healthtalk.no)

Awakening with publication: These researchers took a double Jama news, research, specialist health service - Dagens Medisin

Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases | Dermatology | Jama | Jama Network

The Marie Spångberg Prize 2022 (medical federingen.no)

PUBLICATIONS

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs On Disease Flares in Patients With Rheumatoid Arthritis in Remission: The Arctic Rewind Randomized Clinical Trial-Pub.

Half-dose vs stable-dose conventional synthetic disease modifying antirheumatic drugs and disease flare in patients with rheumatoid arthritis-reply-pubmed (nih.gov)

Project Manager:
Espen A. Haavardsholm
WP2 - PPhenotyping for personalized medicine

BIKE

Biopsies of synovitis in the knee joint from patients with RA and OA

Project Manager:
Hilde Berner Hammer
WP2 - PPhenotyping for personalized medicine

BioTest

Experimental precision medicine

Project Manager:
Guro Løvik Goll
WP2 - PPhenotyping for personalized medicine

Boogie

Dynamics in Bone Turnover Markers in Relation to Glucocorticoid Treatment in Patients With An Inflammatory Joint Disease

Project Manager:
Birgitte Nellemann
WP2 - PPhenotyping for personalized medicine

MDR-RA

The Norwegian study for therapeutic drug monitoring

Project Manager:
Espen A. Haavardsholm
WP1 - Optimized medical interventions

MERINO

Methotrexate in the treatment of erosive hand osteoarthritis

Project Manager:
Ida Bos-Haugen
WP6 - Dechiphering long-term outcomes

NOR-DMARD

The Norwegian register for antirheumatic drugs

Project Manager:
Tore K. Kvien
WP2 - PPhenotyping for personalized medicine

NOR DRUM

The Norwegian study for therapeutic drug monitoring

Project Manager:
Espen A. Haavardsholm
WP1 - Optimized medical interventions

NOR SWITCH

Switching from the original preparation to a biosimilar medicine to patients with inflammatory disease of the joints, intestines or skin.

Project Manager:
Tore K. Kvien
WP2 - PPhenotyping for personalized medicine

Nor-vaC

Immunological response to COVID-19 vaccine in patients on immunosuppressive treatment

Project Manager:
Guro Løvik Goll
WP2 - PPhenotyping for personalized medicine

RIMRA

Rheumatic immune-related side effects in patients treated with immunotherapy

Project Manager:
Marte Schrumpf Heiberg
WP6 - Dechiphering long-term outcomes

SPACE

Early detection of spondyloarthritis

Project Manager:
Karen Minde Fagerli
WP2 - PPhenotyping for personalized medicine

START

Early diagnosis by recently arising arthritis

Project Manager:
Silje Watterdal Syversen
WP2 - PPhenotyping for personalized medicine

ULTRABIT

Longitudinal ultrasound study of patients with rheumatoid arthritis starting treatment with biological DMARD drugs

Project Manager:
Hilde Berner Hammer